{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:30:41Z","timestamp":1694629841596},"reference-count":46,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"DOI":"10.2337\/dc07-zb07","type":"journal-article","created":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T17:28:10Z","timestamp":1182965290000},"page":"1934-1939","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":5,"title":["Gut Hormones, Obesity, Polycystic Ovarian Syndrome, Malignancy, and Lipodystrophy Syndromes"],"prefix":"10.2337","volume":"30","author":[{"given":"Zachary T.","family":"Bloomgarden","sequence":"first","affiliation":[{"name":"Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031217435800600_R1","doi-asserted-by":"crossref","unstructured":"Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology\u200889:1070\u20131077, 1985","DOI":"10.1016\/0016-5085(85)90211-2"},{"key":"2022031217435800600_R2","doi-asserted-by":"crossref","unstructured":"Ballantyne GH: Peptide YY(1\u201336) and peptide YY(3\u201336). Part I. Distribution, release and actions. Obes Surg\u200816:651\u2013658, 2006","DOI":"10.1381\/096089206776944959"},{"key":"2022031217435800600_R3","doi-asserted-by":"crossref","unstructured":"Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR: Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion\u200830:255\u2013262, 1984","DOI":"10.1159\/000199117"},{"key":"2022031217435800600_R4","doi-asserted-by":"crossref","unstructured":"Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, Polak JM, Bloom SR: Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology\u200889:494\u2013499, 1985","DOI":"10.1016\/0016-5085(85)90442-1"},{"key":"2022031217435800600_R5","doi-asserted-by":"crossref","unstructured":"Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR: Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut\u200828:166\u2013170, 1987","DOI":"10.1136\/gut.28.2.166"},{"key":"2022031217435800600_R6","unstructured":"Adrian TE, Savage AP, Fuessl HS, Wolfe K, Besterman HS, Bloom SR: Release of peptide YY (PYY) after resection of small bowel, colon, or pancreas in man. Surgery\u2008101:715\u2013719, 1987"},{"key":"2022031217435800600_R7","doi-asserted-by":"crossref","unstructured":"le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR: Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg\u2008243:108\u2013114, 2006","DOI":"10.1097\/01.sla.0000183349.16877.84"},{"key":"2022031217435800600_R8","doi-asserted-by":"crossref","unstructured":"Halatchev IG, Ellacott KL, Fan W, Cone RD: Peptide YY3\u201336 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology\u2008145:2585\u20132590, 2004","DOI":"10.1210\/en.2003-1754"},{"key":"2022031217435800600_R9","doi-asserted-by":"crossref","unstructured":"Stunkard AJ, McLaren-Hume M: The results of treatment for obesity. Arch Int Med\u2008103:79\u201385, 1959","DOI":"10.1001\/archinte.1959.00270010085011"},{"key":"2022031217435800600_R10","doi-asserted-by":"crossref","unstructured":"Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med\u2008351:2683\u20132693, 2004","DOI":"10.1056\/NEJMoa035622"},{"key":"2022031217435800600_R11","doi-asserted-by":"crossref","unstructured":"Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. JAMA\u2008292:1724\u20131737, 2004","DOI":"10.1001\/jama.292.14.1724"},{"key":"2022031217435800600_R12","doi-asserted-by":"crossref","unstructured":"Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M: Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring)\u200814:1553\u20131561, 2006","DOI":"10.1038\/oby.2006.179"},{"key":"2022031217435800600_R13","doi-asserted-by":"crossref","unstructured":"Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV: Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med\u2008353:249\u2013254, 2005","DOI":"10.1056\/NEJMoa043690"},{"key":"2022031217435800600_R14","doi-asserted-by":"crossref","unstructured":"Meier JJ, Butler AE, Galasso R, Butler PC: Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased \u03b2-cell turnover. Diabetes Care\u200829:1554\u20131559, 2006","DOI":"10.2337\/dc06-0392"},{"key":"2022031217435800600_R15","doi-asserted-by":"crossref","unstructured":"Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes\u200850:1714\u20131719, 2001","DOI":"10.2337\/diabetes.50.8.1714"},{"key":"2022031217435800600_R16","doi-asserted-by":"crossref","unstructured":"Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D: Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab\u2008287:E297\u2013E304, 2004","DOI":"10.1152\/ajpendo.00582.2003"},{"key":"2022031217435800600_R17","doi-asserted-by":"crossref","unstructured":"Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med\u2008346:1623\u20131630, 2002","DOI":"10.1056\/NEJMoa012908"},{"key":"2022031217435800600_R18","doi-asserted-by":"crossref","unstructured":"Weigle DS, Cummings DE, Newby PD, Breen PA, Frayo RS, Matthys CC, Callahan HS, Purnell JQ: Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J Clin Endocrinol Metab\u200888:1577\u20131586, 2003","DOI":"10.1210\/jc.2002-021262"},{"key":"2022031217435800600_R19","doi-asserted-by":"crossref","unstructured":"Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med\u20088:643\u2013644, 2002","DOI":"10.1038\/nm0702-643"},{"key":"2022031217435800600_R20","doi-asserted-by":"crossref","unstructured":"Zavaroni I, Zuccarelli A, Gasparini P, Massironi P, Barilli A, Reaven GM: Can weight gain in healthy, nonobese volunteers be predicted by differences in baseline plasma insulin concentration? J Clin Endocrinol Metab\u200883:3498\u20133500, 1998","DOI":"10.1210\/jc.83.10.3498"},{"key":"2022031217435800600_R21","doi-asserted-by":"crossref","unstructured":"Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E: Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest\u200888:168\u2013173, 1991","DOI":"10.1172\/JCI115274"},{"key":"2022031217435800600_R22","doi-asserted-by":"crossref","unstructured":"McLaughlin T, Abbasi F, Carantoni M, Schaaf P, Reaven G: Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. J Clin Endocrinol Metab\u200884:578\u2013581, 1999","DOI":"10.1210\/jc.84.2.578"},{"key":"2022031217435800600_R23","doi-asserted-by":"crossref","unstructured":"Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall'Aglio E, Delsignore R, Reaven GM: Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism\u200848:989\u2013994, 1999","DOI":"10.1016\/S0026-0495(99)90195-6"},{"key":"2022031217435800600_R24","doi-asserted-by":"crossref","unstructured":"Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab\u200884:165\u2013169, 1999","DOI":"10.1210\/jc.84.1.165"},{"key":"2022031217435800600_R25","doi-asserted-by":"crossref","unstructured":"Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A: Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab\u200887:1017\u20131023, 2002","DOI":"10.1210\/jcem.87.3.8305"},{"key":"2022031217435800600_R26","doi-asserted-by":"crossref","unstructured":"Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab\u200891:492\u2013497, 2006","DOI":"10.1210\/jc.2005-1666"},{"key":"2022031217435800600_R27","doi-asserted-by":"crossref","unstructured":"Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab\u200881:3299\u20133306, 1996","DOI":"10.1210\/jcem.81.9.8784087"},{"key":"2022031217435800600_R28","doi-asserted-by":"crossref","unstructured":"Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS\/Troglitazone Study Group: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab\u200886:1626\u20131632, 2001","DOI":"10.1210\/jc.86.4.1626"},{"key":"2022031217435800600_R29","doi-asserted-by":"crossref","unstructured":"McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Yoo R, Chang RJ, Foster CM, Marshall JC: The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab\u200891:1714\u20131722, 2006","DOI":"10.1210\/jc.2005-1852"},{"key":"2022031217435800600_R30","doi-asserted-by":"crossref","unstructured":"Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS\/Troglitazone Study Group: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab\u200891:48\u201353, 2006","DOI":"10.1210\/jc.2005-1329"},{"key":"2022031217435800600_R31","doi-asserted-by":"crossref","unstructured":"Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab\u200881:952\u2013960, 1996","DOI":"10.1210\/jcem.81.3.8772557"},{"key":"2022031217435800600_R32","doi-asserted-by":"crossref","unstructured":"Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R: Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf)\u200860:241\u2013249, 2004","DOI":"10.1111\/j.1365-2265.2004.01973.x"},{"key":"2022031217435800600_R33","doi-asserted-by":"crossref","unstructured":"Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A: Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab\u200887:2128\u20132133, 2002","DOI":"10.1210\/jcem.87.5.8513"},{"key":"2022031217435800600_R34","doi-asserted-by":"crossref","unstructured":"Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A: Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab\u200887:2134\u20132138, 2002","DOI":"10.1210\/jcem.87.5.8387"},{"key":"2022031217435800600_R35","doi-asserted-by":"crossref","unstructured":"Urbanek M, Woodroffe A, Ewens KG, Diamanti-Kandarakis E, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS: Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab\u200890:6623\u20136629, 2005","DOI":"10.1210\/jc.2005-0622"},{"key":"2022031217435800600_R36","doi-asserted-by":"crossref","unstructured":"Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes\u200838:1165\u20131174, 1989","DOI":"10.2337\/diabetes.38.9.1165"},{"key":"2022031217435800600_R37","doi-asserted-by":"crossref","unstructured":"Legro RS: Polycystic ovary syndrome: phenotype to genotype. Endocrinol Metab Clin North Am\u200828:379\u2013396, 1999","DOI":"10.1016\/S0889-8529(05)70075-X"},{"key":"2022031217435800600_R38","doi-asserted-by":"crossref","unstructured":"Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE: Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA\u2008286:2421\u20132426, 2001","DOI":"10.1001\/jama.286.19.2421"},{"key":"2022031217435800600_R39","doi-asserted-by":"crossref","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med\u2008346:393\u2013403, 2002","DOI":"10.1056\/NEJMoa012512"},{"key":"2022031217435800600_R40","doi-asserted-by":"crossref","unstructured":"Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab\u200890:1929\u20131935, 2005","DOI":"10.1210\/jc.2004-1045"},{"key":"2022031217435800600_R41","doi-asserted-by":"crossref","unstructured":"Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab\u200890:3863\u20133870, 2005","DOI":"10.1210\/jc.2004-1958"},{"key":"2022031217435800600_R42","doi-asserted-by":"crossref","unstructured":"Palomba S, Orio F Jr, Nardo LG, Falbo A, Russo T, Corea D, Doldo P, Lombardi G, Tolino A, Colao A, Zullo F: Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab\u200889:4801\u20134809, 2004","DOI":"10.1210\/jc.2004-0689"},{"key":"2022031217435800600_R43","doi-asserted-by":"crossref","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med\u2008348:1625\u20131638, 2003","DOI":"10.1056\/NEJMoa021423"},{"key":"2022031217435800600_R44","doi-asserted-by":"crossref","unstructured":"King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science\u2008302:643\u2013646, 2003","DOI":"10.1126\/science.1088759"},{"key":"2022031217435800600_R45","doi-asserted-by":"crossref","unstructured":"Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA\u2008293:2479\u20132486, 2005","DOI":"10.1001\/jama.293.20.2479"},{"key":"2022031217435800600_R46","doi-asserted-by":"crossref","unstructured":"Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care\u200829:254\u2013258, 2006","DOI":"10.2337\/diacare.29.02.06.dc05-1558"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/7\/1934\/597737\/zdc00707001934.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/7\/1934\/597737\/zdc00707001934.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T18:38:18Z","timestamp":1647110298000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/30\/7\/1934\/26545\/Gut-Hormones-Obesity-Polycystic-Ovarian-Syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc07-zb07","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}